Biologics for the Use in Chronic Spontaneous Urticaria: When and Which
Author:
Publisher
Elsevier BV
Subject
Immunology and Allergy
Reference134 articles.
1. A randomized phase IIb study of mavrilimumab and golimumab in rheumatoid arthritis;Weinblatt;Arthritis Rheumatol,2018
2. Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial;Hanauer;Gastroenterology,2006
3. Dual neutralization of both interleukin 17A and interleukin 17F with bimekizumab in patients with psoriasis: results from BE ABLE 1, a 12-week randomized, double-blinded, placebo-controlled phase 2b trial;Papp;J Am Acad Dermatol,2018
4. Anti-IL-17 receptor antibody AMG 827 leads to rapid clinical response in subjects with moderate to severe psoriasis: results from a phase I, randomized, placebo-controlled trial;Papp;J Invest Dermatol,2012
5. Clinical pharmacology of the anti-IL-17 receptor antibody brodalumab (KHK4827) in Japanese normal healthy volunteers and Japanese subjects with moderate to severe psoriasis: a randomized, dose-escalation, placebo-controlled study;Osamu;J Dermatol Sci,2014
Cited by 84 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A comprehensive analysis on the safety of two biologics dupilumab and omalizumab;Frontiers in Medicine;2024-08-08
2. Strategien bei chronischer spontaner Urtikaria;HNO Nachrichten;2024-08
3. In chronic spontaneous urticaria, increased Galectin‐9 expression on basophils and eosinophils is linked to high disease activity, endotype‐specific markers, and response to omalizumab treatment;Allergy;2024-07-18
4. Serum Concentration of IL-5 Receptor (IL-5R) and Associations with Disease Severity in Patients with Chronic Spontaneous Urticaria (CSU) and Atopic Dermatitis (AD);International Journal of Molecular Sciences;2024-07-11
5. Targeted therapy for immune mediated skin diseases. What should a dermatologist know?;Anais Brasileiros de Dermatologia;2024-07
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3